LASANSELasa Supergenerics Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 13 Feb, 2026 · 15:42 IST

Lasa Supergenerics Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

Going ConcernQualified OpinionRevenue DeclinePat NegativeExceptional ItemResults View source PDFExplain this filing

LASA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction

Awaiting price reaction for this filing.

AI summary

Lasa Supergenerics reported a net loss of Rs 255.47 lakhs for Q3 FY26, against a profit of Rs 549.39 lakhs in the year-ago quarter. Revenue from operations collapsed to Rs 219.93 lakhs from Rs 3,307.99 lakhs in Q3 FY25, a steep ~93% YoY decline, and fell further from Rs 306.11 lakhs in Q2 FY26. For the nine months ended December 2025, the company posted a net loss of Rs 2,992.59 lakhs versus a small profit of Rs 273.35 lakhs a year earlier. The results include an exceptional loss of Rs 824.53 lakhs from a May 18, 2025 fire at the company's main factory in Ratnagiri that destroyed uninsured inventory, plant, and equipment and halted all production. The auditor (Gupta Rustagi & Co.) flagged a qualified review opinion citing the fire, going concern uncertainty, dormant bank accounts, and a force majeure dispute with a customer.

Likely market impact

This is a severely negative filing for shareholders: production is fully halted, the company is exploring contract manufacturing, key assets were uninsured, and the auditor has raised a going concern flag — meaning there is real doubt about the company's ability to continue operations. The stock is likely to face significant selling pressure given the operational shutdown and mounting losses.